Parabilis Reports 72.2% ORR in Zolucatetide Study; FDA Aligns on Phase 3
Parabilis reported a 72.2% objective response rate (13/18) at doses of at least 450 mg in a 32-week Phase 1/2 analysis of zolucatetide in desmoid tumors. The company said the FDA aligned on dose, placebo-controlled design and progression-free survival for a planned Phase 3 trial starting in H1 2027; disease control rate was 100% across 46 evaluable patients.
Parabilis reported updated Phase 1/2 zolucatetide data in desmoid tumors, showing a 72.2% ORR in a 32-week analysis (13/18) at ≥450 mg, 100% DCR across 46 evaluable patients, and FDA alignment on dose, placebo-controlled design, and PFS for a planned Phase 3 starting H1 2027.Material DetailsContext…